Aaron Cowen’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aaron Cowen’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,670	Closed	-$276K	–	98
2022 Q4	$276K	Buy	+2,670	New	+$251K	0.01%	81

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aaron Cowen's BMRN Position: Q1 2023 in Review

Aaron Cowen sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 2,670 shares — an estimated $276K sold.

Aaron Cowen first reported a position in BMRN in Q4 2022 and held it in 1 quarter. The position peaked at $276K in Q4 2022. 553 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Aaron Cowen reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Aaron Cowen sold 2,670 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $276K.
Aaron Cowen first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Aaron Cowen's BioMarin Pharmaceuticals position peaked at $276K in Q4 2022.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Suvretta Capital Management's 13F filing for Q1 2023, filed 15 May 2023.